A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

NCT00402077 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight
Obesity

Interventions

DRUG: pramlintide acetate
DRUG: sibutramine
DRUG: phentermine
DRUG: placebo

Sponsor

AstraZeneca